Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis

Teppei Yamaguchi, Sumito Isogai, Takuya Okamura, Sakurako Uozu, Yuki Mieno, Tami Hoshino, Yasuhiro Goto, Masamichi Hayashi, Toru Nakanishi, Kazuyoshi Imaizumi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.

Original languageEnglish
Pages (from-to)78-82
Number of pages5
JournalCase Reports in Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - 22-05-2015

Fingerprint

Continuous Ambulatory Peritoneal Dialysis
Non-Small Cell Lung Carcinoma
Pharmacokinetics
Lung Neoplasms
Ascitic Fluid
Brain
Peritoneal Dialysis
Epidermal Growth Factor Receptor
Chronic Kidney Failure
gefitinib
Exons
Diarrhea
Radiotherapy
Nucleotides
Neoplasm Metastasis
Recurrence
Mutation

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Yamaguchi, Teppei ; Isogai, Sumito ; Okamura, Takuya ; Uozu, Sakurako ; Mieno, Yuki ; Hoshino, Tami ; Goto, Yasuhiro ; Hayashi, Masamichi ; Nakanishi, Toru ; Imaizumi, Kazuyoshi. / Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. In: Case Reports in Oncology. 2015 ; Vol. 8, No. 1. pp. 78-82.
@article{fbddc9c6482f49f3b5832d0639d543e1,
title = "Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis",
abstract = "A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.",
author = "Teppei Yamaguchi and Sumito Isogai and Takuya Okamura and Sakurako Uozu and Yuki Mieno and Tami Hoshino and Yasuhiro Goto and Masamichi Hayashi and Toru Nakanishi and Kazuyoshi Imaizumi",
year = "2015",
month = "5",
day = "22",
doi = "10.1159/000375485",
language = "English",
volume = "8",
pages = "78--82",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

Yamaguchi, T, Isogai, S, Okamura, T, Uozu, S, Mieno, Y, Hoshino, T, Goto, Y, Hayashi, M, Nakanishi, T & Imaizumi, K 2015, 'Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis', Case Reports in Oncology, vol. 8, no. 1, pp. 78-82. https://doi.org/10.1159/000375485

Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis. / Yamaguchi, Teppei; Isogai, Sumito; Okamura, Takuya; Uozu, Sakurako; Mieno, Yuki; Hoshino, Tami; Goto, Yasuhiro; Hayashi, Masamichi; Nakanishi, Toru; Imaizumi, Kazuyoshi.

In: Case Reports in Oncology, Vol. 8, No. 1, 22.05.2015, p. 78-82.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics of gefitinib in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis

AU - Yamaguchi, Teppei

AU - Isogai, Sumito

AU - Okamura, Takuya

AU - Uozu, Sakurako

AU - Mieno, Yuki

AU - Hoshino, Tami

AU - Goto, Yasuhiro

AU - Hayashi, Masamichi

AU - Nakanishi, Toru

AU - Imaizumi, Kazuyoshi

PY - 2015/5/22

Y1 - 2015/5/22

N2 - A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.

AB - A 72-year-old man undergoing continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure and who had undergone right upper lobectomy for lung adenocarcinoma (pT2aN0M0) 2 years ago was admitted for recurrence of lung cancer presenting as multiple brain metastases. An epidermal growth factor receptor mutation analysis of his lung cancer revealed a deletion of 15 nucleotides (E746-A750) in exon 19. After whole-brain radiotherapy, we started daily administration of 250 mg gefitinib under the continuation of CAPD and performed a pharmacokinetic analysis. We speculated that the plasma concentration of gefitinib reached the steady state at least by day 16 after the start of gefitinib (626.6 ng/ml at trough level). On day 46, the plasma concentration was 538.4 ng/ml at trough level and the concentration in the peritoneal dialysis fluid was 34.6 ng/ml, suggesting that CAPD appeared to have little effect on the pharmacokinetics of gefitinib. During gefitinib therapy, there were no significant adverse events except for grade 2 diarrhea. Gefitinib could be safely administered to a patient undergoing CAPD.

UR - http://www.scopus.com/inward/record.url?scp=84929578695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929578695&partnerID=8YFLogxK

U2 - 10.1159/000375485

DO - 10.1159/000375485

M3 - Article

VL - 8

SP - 78

EP - 82

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -